Here are all the tariffs staying in place after Supreme Court ruling

• Automotive sector still faces 25% tariffs on foreign vehicles and parts, with some countries like UK and Japan negotiating reductions to 10-15%; major automakers like GM and Ford report multi-billion dollar charges ($2-4 billion annually)
• Steel and aluminum tariffs remain at 50%, affecting home appliances, electronics, and beverage can producers, while furniture faces 25% tariffs set to increase to 100%
• Semiconductors face 25% tariffs effective last month, and pharmaceuticals could face tariffs up to 250% unless drugmakers increase US production, though nine major companies secured exemptions by agreeing to lower prices

Summary

The Supreme Court struck down President Trump's tariffs imposed under the International Emergency Economic Powers Act (IEEPA) in a 6-3 ruling on Friday, citing presidential authority overreach. However, tariffs enacted under Section 232 of the Trade Expansion Act of 1962—justified on national security grounds—remain intact, leaving several key industries facing continued high levies.

Industries Still Affected:

Automotive: Foreign vehicles and auto parts face 25% tariffs, though deals with the UK, Japan, and South Korea have reduced some rates to 10-15%. Major automakers are absorbing significant costs: Mercedes-Benz reported a $1.2 billion hit in 2025; Ford incurred approximately $2 billion in tariff charges; General Motors logged $3.1 billion in 2025 and anticipates $3-4 billion in 2026.

Furniture: 25% tariffs on upholstered furniture, kitchen cabinets, and vanities remain, with a scheduled increase. Timber and lumber imports face 10% tariffs. This sector is particularly vulnerable as most goods are imported.

Steel and Aluminum: 50% tariffs continue, impacting home appliances, electronics, and beverage cans.

Semiconductors: 25% tariffs on certain chips and chipmaking equipment, effective last month, stay in place.

Pharmaceuticals: Trump has threatened tariffs as high as 250% but paused implementation after nine major drugmakers—including Merck, Bristol Myers Squibb, Amgen, and Novartis—agreed to voluntarily lower prices for three years.

Market Implications: Companies face multi-billion dollar charges and supply chain disruptions. The ruling eliminates "reciprocal" tariffs but preserves substantial trade barriers affecting manufacturing costs, consumer prices, and corporate earnings across multiple sectors.